Overview

Study to Evaluate the Safety,Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The protocol describes a double-blind study to evaluate the Pharmacokinetics and safety of a new formulation of oritavancin by adjusting infusion time, concentration and reconstitution/administration solutions, of a single 1200 mg intravenous (IV) infusion of oritavancin
Phase:
Phase 1
Details
Lead Sponsor:
The Medicines Company
Treatments:
Oritavancin